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Supplementary Materials and Methods 
 
 
DNase I inactivation experiment. Incubations were performed in PCR tubes on a Bio-Rad C1000 Thermal Cycler. Samples 
including DNase I (Samples B-F in S1 Fig) consisted of 90 µL MHB, 5 µL NaHCO3 (100 mM), and 5 µL NEB DNase I (2000 
U/mL). Nuclease-free water was used in place of DNase I in the control sample (Sample A in S1 Fig). After vortexing to mix, 
5 µL of each suspension was added to 45 µL QuickExtract DNA Extraction Solution (Lucigen). Samples A and B were 
heated at 65 °C for 6 min and 98 °C for 4 min. Sample C was heated at 65 °C for 4 min and 98 °C for 3 min. Sample D was 
heated at 65 °C for 3 min and 98 °C for 2 min.  Sample E was heated at 65 °C for 2 min and 98 °C for 1 min.  Sample F 
was heated at 65 °C for 1 min and 98 °C for 1 min. After each heating step was completed, the samples were placed on an 
ice block. DNase I activity was tested by adding 15 µL of a spike-in control of Ng DNA (1/20 dilution of stock Cq 19, expected 
concentration in PCR in this experiment to be a Cq of 23.3) to 15 µL of the Samples A-F in PCR tubes, samples were heated 
to 37 °C for 5 min, and then the samples were quantified in qPCR, as described in the main methods section.   
 
DNA digestion of the lambda spike-in. Seven or eight 1.25 mL aliquots of clinical urine samples were centrifuged in 2 
mL microcentrifuge tubes (VWR) for 5 min at 1,000 x g (Eppendorf 5418R). Pellets were re-suspended in 250 µL GWM 
containing a lambda DNA spike-in (see below for preparation). All working suspensions were then pooled together. To 
generate the (+) DNase I controls, 320 µL aliquots of the working suspensions were added to 40 µL 10X DNase 
I Reaction Buffer (NEB), 20 µL DNase I (2,000 U/mL) (NEB), and 20 µL nuclease-free water. Nuclease-free water was 
used in place of DNase I in the (-) DNase I control sample. Suspensions were then vortexed, quickly spun on a benchtop 
microcentrifuge (Labnet) at 2,000 x g for 2-3 sec, and incubated at 37 °C for 15 min on a heat block 
(ThermoScientific Digital Shaking Drybath). Suspensions were then removed from the heat block, vortexed, and spun on 
a benchtop microcentrifuge (Labnet) at 2,000 x g for 2-3 sec. After mixing, 20 µL of each suspension was added to 80 
µL QuickExtract DNA Extraction Solution (Lucigen). Samples were heated at 65 °C for 6 min and 98 °C for 4 min on a 
BioRad C1000 Thermal Cycler. DNase I activity was tested by subtracting the concentration of lambda DNA in the (-
) DNase I control from the concentration in the (+) DNase I control tube. Quantification of DNA was done with qPCR 
(Roche, LightCycler 96) as described in the main methods. As in the clinical nuc-aAST, we used 2 µL of template per 10 
µL qPCR reaction.   
   
The lambda DNA spike-in was prepared as follows. 12.5 µL lambda phage DNA (7.1x105 copies/µL, as quantified with 
ddPCR) (QX200, Bio-Rad) in 0.5X TE Buffer was mixed with 1238 µL Graver-Wade Medium (GWM).  
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